The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 54 | — | 20.1x | Near average | |
Growth | 27 | — | 5.6% | Below average | |
Quality | 56 | 1582.5% | 7.6% | Near average | |
Safety | 59 | 2.5x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Immix Biopharma, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Immix Biopharma, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
IMMX stock shows stability in the price target at 17 dollars with a consensus from only one analyst, indicating high optimism but with a very limited coverage range that raises concentration risk. The significant gap between the current price (8.78) and the lowest price target (14) reflects expectations of strong growth; however, the absence of changes in valuations over the past 30 days suggests a state of anticipation for tangible clinical or financial results.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.